scholarly journals KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer

2021 ◽  
Vol 11 (10) ◽  
Author(s):  
Ho Tsoi ◽  
Ellen PS Man ◽  
Man‐Hong Leung ◽  
Ka‐Chun Mok ◽  
Ka‐Man Chau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nuclear Import ◽  
Splice Variant ◽  
Tamoxifen Resistance

237 Splice variant profiling in relation to tamoxifen resistance in breast cancer

2010 ◽  
Vol 8 (5) ◽  
pp. 62
Author(s):  
L.D. Zhang ◽  
Y.K. Chan ◽  
Y.C. Ip ◽  
W.H. Tsang ◽  
Y.N. Cheung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Splice Variant ◽  
Tamoxifen Resistance

scholarly journals CD63 + Cancer‐Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR‐22

2020 ◽  
Vol 7 (21) ◽  
pp. 2002518
Author(s):  
Yuan Gao ◽  
Xiaoju Li ◽  
Cheng Zeng ◽  
Chenlin Liu ◽  
Qiang Hao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Tamoxifen Resistance ◽  
Cancer Associated Fibroblasts

scholarly journals From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3688
Author(s):  
Jéssica Fernanda Barazetti ◽  
Tayana Shultz Jucoski ◽  
Tamyres Mingorance Carvalho ◽  
Rafaela Nasser Veiga ◽  
Ana Flávia Kohler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Estrogen Receptor Alpha ◽  
Expression Patterns ◽  
Tamoxifen Resistance ◽  
Hormone Receptor Positive ◽  
Current State ◽  
Main Driver ◽  
Underlying Mechanisms ◽  
Multiple Signaling

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among women. Two thirds of patients are classified as hormone receptor positive, based on expression of estrogen receptor alpha (ERα), the main driver of breast cancer cell proliferation, and/or progesterone receptor, which is regulated by ERα. Despite presenting the best prognosis, these tumors can recur when patients acquire resistance to treatment by aromatase inhibitors or antiestrogen such as tamoxifen (Tam). The mechanisms that are involved in Tam resistance are complex and involve multiple signaling pathways. Recently, roles for microRNAs and lncRNAs in controlling ER expression and/or tamoxifen action have been described, but the underlying mechanisms are still little explored. In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. In the future, this knowledge can be used to identify patients at a greater risk of relapse due to the expression patterns of ncRNAs that impact response to Tam, in order to guide their treatment more efficiently and possibly to design therapeutic strategies to bypass mechanisms of resistance.

scholarly journals HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer

2021 ◽  
Author(s):  
Han Zhang ◽  
Jinlu Wang ◽  
Jingtong Li ◽  
Zhou Xiaoping ◽  
Lei Yin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tamoxifen Resistance ◽  
Key Factor

scholarly journals Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Oncogene ◽  
2007 ◽  
Vol 26 (49) ◽  
pp. 6997-7005 ◽  
Author(s):  
J Bostner ◽  
M Ahnström Waltersson ◽  
T Fornander ◽  
L Skoog ◽  
B Nordenskjöld ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tamoxifen Resistance ◽  
Postmenopausal Breast Cancer ◽  
Predictors Of Recurrence

scholarly journals G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

2011 ◽  
Vol 128 (2) ◽  
pp. 457-466 ◽  
Author(s):  
Atanas Ignatov ◽  
Tanja Ignatov ◽  
Christine Weißenborn ◽  
Holm Eggemann ◽  
Joachim Bischoff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
G Protein ◽  
Tamoxifen Resistance ◽  
G Protein Coupled
Sign in / Sign up

Export Citation Format

Share Document